JO3581B1 - مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي - Google Patents
مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسوميInfo
- Publication number
- JO3581B1 JO3581B1 JOP/2015/0256A JOP20150256A JO3581B1 JO 3581 B1 JO3581 B1 JO 3581B1 JO P20150256 A JOP20150256 A JO P20150256A JO 3581 B1 JO3581 B1 JO 3581B1
- Authority
- JO
- Jordan
- Prior art keywords
- synthase
- compounds useful
- piperidine compounds
- microsomal prostaglandin
- novel methyl
- Prior art date
Links
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical class CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 title 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
- 229960002986 dinoprostone Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003228 microsomal effect Effects 0.000 title 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير مركبات لها الصيغة 1، أو ملح مقبول صيدليًا منها، 1، حيث تكون R، R1، وG على النحو الموصوف هنا؛ طرق لتحضير المركبات؛ واستخدام المركبات لعلاج الألم و/أو الالتهاب المصاحب لالتهاب المفاصل أو الالتهاب العظمي المفصلي.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072196P | 2014-10-29 | 2014-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3581B1 true JO3581B1 (ar) | 2020-07-05 |
Family
ID=54478248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2015/0256A JO3581B1 (ar) | 2014-10-29 | 2015-10-18 | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9962375B2 (ar) |
| EP (1) | EP3230278B1 (ar) |
| JP (1) | JP6393830B2 (ar) |
| KR (1) | KR101898829B1 (ar) |
| CN (1) | CN107074829B (ar) |
| AR (2) | AR102362A1 (ar) |
| AU (1) | AU2015339644B2 (ar) |
| CA (1) | CA2963321C (ar) |
| CL (1) | CL2017001017A1 (ar) |
| CY (1) | CY1122534T1 (ar) |
| DK (1) | DK3230278T3 (ar) |
| EA (1) | EA032428B1 (ar) |
| ES (1) | ES2773439T3 (ar) |
| HR (1) | HRP20200216T1 (ar) |
| HU (1) | HUE047895T2 (ar) |
| JO (1) | JO3581B1 (ar) |
| LT (1) | LT3230278T (ar) |
| MX (1) | MX376479B (ar) |
| NZ (1) | NZ730724A (ar) |
| PL (1) | PL3230278T3 (ar) |
| PT (1) | PT3230278T (ar) |
| RS (1) | RS59783B1 (ar) |
| SI (1) | SI3230278T1 (ar) |
| TW (1) | TWI605039B (ar) |
| WO (1) | WO2016069376A1 (ar) |
| ZA (1) | ZA201702198B (ar) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201627299A (zh) | 2014-10-29 | 2016-08-01 | 美國禮來大藥廠 | 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物 |
| CN111655253A (zh) | 2018-01-09 | 2020-09-11 | 杨百翰大学 | 用于用汉黄芩素治疗疼痛的组合物和方法 |
| CN108558806B (zh) * | 2018-05-31 | 2020-04-17 | 南京药石科技股份有限公司 | 一种5-氧代-四氢吡喃-3-羧酸酯的关键中间体及其制备方法 |
| WO2020061475A2 (en) * | 2018-09-21 | 2020-03-26 | The Johns Hopkins University | Compositions and methods for treating metabolic disorders |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| AU2020374947C1 (en) | 2019-10-31 | 2025-05-08 | Forty Seven, LLC | Anti-CD47 and anti-CD20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| JP7564888B2 (ja) | 2020-05-01 | 2024-10-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物 |
| TWI854147B (zh) * | 2020-08-21 | 2024-09-01 | 南韓商治納輔醫藥科技有限公司 | 對前列腺素e2受體具有抑制活性的新穎化合物及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024546851A (ja) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| JPWO2023127883A1 (ar) | 2021-12-28 | 2023-07-06 | ||
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CA3249472A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | KIRSTEN G12D RAT SARCOMA VIRUS MODULATOR COMPOUNDS |
| AU2023298558A1 (en) | 2022-07-01 | 2024-12-19 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355010B1 (en) * | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
| EP1627869B1 (en) * | 2003-05-20 | 2012-05-02 | Ajinomoto Co., Inc. | Vanilloid receptor modulators |
| US20050239921A1 (en) * | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| EP2491007B1 (en) * | 2009-10-23 | 2013-09-25 | Boehringer Ingelheim International GmbH | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| US20160122330A1 (en) * | 2013-06-20 | 2016-05-05 | Novasaid Ab | Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors |
| TW201627299A (zh) | 2014-10-29 | 2016-08-01 | 美國禮來大藥廠 | 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物 |
-
2015
- 2015-10-18 JO JOP/2015/0256A patent/JO3581B1/ar active
- 2015-10-19 TW TW104134250A patent/TWI605039B/zh active
- 2015-10-19 AR ARP150103382A patent/AR102362A1/es active IP Right Grant
- 2015-10-22 US US15/520,462 patent/US9962375B2/en active Active
- 2015-10-22 CN CN201580058595.9A patent/CN107074829B/zh active Active
- 2015-10-22 PL PL15791432T patent/PL3230278T3/pl unknown
- 2015-10-22 CA CA2963321A patent/CA2963321C/en active Active
- 2015-10-22 WO PCT/US2015/056960 patent/WO2016069376A1/en not_active Ceased
- 2015-10-22 HR HRP20200216TT patent/HRP20200216T1/hr unknown
- 2015-10-22 NZ NZ730724A patent/NZ730724A/en unknown
- 2015-10-22 ES ES15791432T patent/ES2773439T3/es active Active
- 2015-10-22 LT LTEP15791432.6T patent/LT3230278T/lt unknown
- 2015-10-22 PT PT157914326T patent/PT3230278T/pt unknown
- 2015-10-22 EA EA201790766A patent/EA032428B1/ru not_active IP Right Cessation
- 2015-10-22 SI SI201531036T patent/SI3230278T1/sl unknown
- 2015-10-22 AU AU2015339644A patent/AU2015339644B2/en active Active
- 2015-10-22 DK DK15791432.6T patent/DK3230278T3/da active
- 2015-10-22 MX MX2017005659A patent/MX376479B/es active IP Right Grant
- 2015-10-22 RS RS20200015A patent/RS59783B1/sr unknown
- 2015-10-22 HU HUE15791432A patent/HUE047895T2/hu unknown
- 2015-10-22 JP JP2017522866A patent/JP6393830B2/ja active Active
- 2015-10-22 KR KR1020177011303A patent/KR101898829B1/ko active Active
- 2015-10-22 EP EP15791432.6A patent/EP3230278B1/en active Active
-
2017
- 2017-03-29 ZA ZA2017/02198A patent/ZA201702198B/en unknown
- 2017-04-24 CL CL2017001017A patent/CL2017001017A1/es unknown
-
2018
- 2018-05-07 US US15/972,699 patent/US20180250282A1/en not_active Abandoned
-
2020
- 2020-01-29 CY CY20201100076T patent/CY1122534T1/el unknown
-
2024
- 2024-10-02 AR ARP240102678A patent/AR134022A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3581B1 (ar) | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي | |
| NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
| SA520411125B1 (ar) | Nlrp مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| EA201691442A1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| TW201612158A (en) | Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
| MX376283B (es) | Compuestos de imidazopiridazina. | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| MX388170B (es) | Polimorfos de selinexor | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| MX2016015247A (es) | Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc). | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 | |
| MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
| EA201692090A1 (ru) | Полициклические активаторы herg | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |